Avatar
Deutsche Welle News source @dw.com · Bonn 🇩🇪· 16h

An international investigation reveals that Merck's commercial strategy for its cancer drug Keytruda, which costs over R$20,000 in Brazil, employs complex legal and pricing tactics to control access, thereby making it increasingly inaccessible to many patients worldwide, despite its significant role in treating various cancers and generating billions in revenue. #CancerTreatment #PharmaceuticalIndustry #HealthInequality

Link Preview
www.dw.com
Como um remédio de ponta contra câncer se tornou inacessível
Investigação revela que estratégia comercial da farmacéutica Merck para lucrar e assegurar patente do medicamento oncológico Keytruda vem dificultando o acesso de muitos pacientes ao tratamento.
Avatar
Deutsche Welle News source @dw.com · Bonn 🇩🇪· 16h

An international investigation reveals that pharmaceutical company Merck's commercial strategy for the cancer drug Keytruda has been obstructing access to treatment for many patients worldwide due to its exorbitant pricing and extensive patent protections. #CancerTreatment #PharmaceuticalIndustry #PatientAccess

Link Preview
www.dw.com
Como um remédio de ponta contra câncer se tornou inacessível
Investigação revela que estratégia comercial da farmacêutica Merck para lucrar e assegurar patente do medicamento oncológico Keytruda vem dificultando o acesso de muitos pacientes ao tratamento.
Avatar
The New York Times News source @nytimes.com · New York City 🇺🇸· 4w

#PharmaceuticalIndustry #DrugPricing #HealthcareReform

Link Preview
www.nytimes.com
How TrumpRx Drug Prices Compare With Those in Other Countries
Rebecca Robbins covers the pharmaceutical industry. She oversaw data collection from pharmacies in Canada, Denmark, France, Germany, Italy, Japan, Switzerland and Britain.
Avatar
Yahoo News source @yahoo.com · Sunnyvale, California 🇺🇸· Mar 13

#PharmaceuticalIndustry #HealthcareCosts #PrescriptionDrugs

Link Preview
www.yahoo.com
Advocates push lawmakers to end tax break for drug commercials, advertising
Advocates argue that some drug companies spend more on executive salaries, stock buybacks, and advertising than they do on research and development, while pharmaceutical companies claim rising prescription drug costs are driven by research and development expenses.
Avatar
The New York Times News source @nytimes.com · New York City 🇺🇸· Feb 27

#HenriettaLacks #MedicalEthics #PharmaceuticalIndustry

Link Preview
www.nytimes.com
Henrietta Lacks's Family Settles Suit With Novartis Over Use of Her Cells
The pharmaceutical giant Novartis has reached a settlement with the family of Henrietta Lacks, a Black woman whose cells were taken from her without her consent in 1951, when she was dying of cervical cancer in a segregated ward at Johns Hopkins Hospital in Baltimore.
Avatar
CBS News News source @cbsnews.com · New York 🇺🇸· Feb 27

#HenriettaLacks #MedicalEthics #PharmaceuticalIndustry

Link Preview
www.cbsnews.com
Novartis settles with woman's estate over use of her "stolen" cells to advance medicine
Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advances, including the polio vaccine.
Avatar
AP NEWS News source @apnews.com · New York City 🇺🇸· Feb 27

#HenriettaLacks #MedicalEthics #PharmaceuticalIndustry

Link Preview
apnews.com
Novartis settles with Henrietta Lacks' estate over use of her 'stolen' cells to advance medicine
Novartis has settled a lawsuit by the estate of Henrietta Lacks that alleged the pharmaceutical giant unjustly profited off her cells, which were taken from her tumor without her knowledge in 1951 and reproduced in labs to enable major medical advancements, including the polio vaccine.
Avatar
CNBC News source @cnbc.com · New Jersey 🇺🇸· Jan 30

#EliLilly #ObesityTreatment #PharmaceuticalIndustry

Link Preview
www.cnbc.com
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.